Literature DB >> 34616876

A late endosome signaling hub that couples PI3Kα and WNT/β-catenin signaling in breast cancer.

Samuel J Rodgers1, Sabryn A Hamila1, Christina A Mitchell1, Lisa M Ooms1.   

Abstract

AKT is the central phosphoinositide 3-kinase (PI3K) signaling effector, however, PIK3CA (p110α subunit of PI3Kα)-mutant estrogen receptor-positive (ER+) breast cancers exhibit minimal AKT activation and the downstream signaling is poorly characterized. We discovered that a subset of PIK3CA-mutant ER+ breast cancers exhibit increased inositol polyphosphate 4-phosphatase type II (INPP4B) expression, which promotes late endosome formation and glycogen synthase kinase 3 beta (GSK3β) trafficking, leading to enhanced Wingless-related integration site (WNT)/catenin beta 1 (β-catenin) activation.
© 2021 Taylor & Francis Group, LLC.

Entities:  

Keywords:  INPP4B; PIK3CA; WNT/β-catenin; cell proliferation; late endosome

Year:  2021        PMID： 34616876      PMCID： PMC8489923          DOI： 10.1080/23723556.2021.1954470

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.

Authors:  Clare G Fedele; Lisa M Ooms; Miriel Ho; Jessica Vieusseux; Sandra A O'Toole; Ewan K Millar; Elena Lopez-Knowles; Absorn Sriratana; Rajendra Gurung; Laura Baglietto; Graham G Giles; Charles G Bailey; John E J Rasko; Benjamin J Shields; John T Price; Philip W Majerus; Robert L Sutherland; Tony Tiganis; Catriona A McLean; Christina A Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-02       Impact factor: 11.205

2.  Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML.

Authors:  Sewa Rijal; Shaun Fleming; Nik Cummings; Natalie K Rynkiewicz; Lisa M Ooms; Nhu-Y N Nguyen; Tse-Chieh Teh; Sharon Avery; Julie F McManus; Anthony T Papenfuss; Catriona McLean; Mark A Guthridge; Christina A Mitchell; Andrew H Wei
Journal:  Blood       Date:  2015-03-03       Impact factor: 22.113

3.  INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.

Authors:  I Dzneladze; R He; J F Woolley; M H Son; M H Sharobim; S A Greenberg; M Gabra; C Langlois; A Rashid; A Hakem; N Ibrahimova; A Arruda; B Löwenberg; P J M Valk; M D Minden; L Salmena
Journal:  Leukemia       Date:  2015-03-04       Impact factor: 11.528

4.  Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Fabrice André; Eva Ciruelos; Gabor Rubovszky; Mario Campone; Sibylle Loibl; Hope S Rugo; Hiroji Iwata; Pierfranco Conte; Ingrid A Mayer; Bella Kaufman; Toshinari Yamashita; Yen-Shen Lu; Kenichi Inoue; Masato Takahashi; Zsuzsanna Pápai; Anne-Sophie Longin; David Mills; Celine Wilke; Samit Hirawat; Dejan Juric
Journal:  N Engl J Med       Date:  2019-05-16       Impact factor: 91.245

5.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

Authors:  Krishna M Vasudevan; David A Barbie; Michael A Davies; Rosalia Rabinovsky; Chontelle J McNear; Jessica J Kim; Bryan T Hennessy; Hsiuyi Tseng; Panisa Pochanard; So Young Kim; Ian F Dunn; Anna C Schinzel; Peter Sandy; Sebastian Hoersch; Qing Sheng; Piyush B Gupta; Jesse S Boehm; Jan H Reiling; Serena Silver; Yiling Lu; Katherine Stemke-Hale; Bhaskar Dutta; Corwin Joy; Aysegul A Sahin; Ana Maria Gonzalez-Angulo; Ana Lluch; Lucia E Rameh; Tyler Jacks; David E Root; Eric S Lander; Gordon B Mills; William C Hahn; William R Sellers; Levi A Garraway
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

6.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

Authors:  Christina Gewinner; Zhigang C Wang; Andrea Richardson; Julie Teruya-Feldstein; Dariush Etemadmoghadam; David Bowtell; Jordi Barretina; William M Lin; Lucia Rameh; Leonardo Salmena; Pier Paolo Pandolfi; Lewis C Cantley
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

7.  Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes.

Authors:  Vincent F Taelman; Radoslaw Dobrowolski; Jean-Louis Plouhinec; Luis C Fuentealba; Peggy P Vorwald; Iwona Gumper; David D Sabatini; Edward M De Robertis
Journal:  Cell       Date:  2010-12-23       Impact factor: 41.582

8.  INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.

Authors:  Samuel J Rodgers; Lisa M Ooms; Viola M J Oorschot; Ralf B Schittenhelm; Elizabeth V Nguyen; Sabryn A Hamila; Natalie Rynkiewicz; Rajendra Gurung; Matthew J Eramo; Absorn Sriratana; Clare G Fedele; Franco Caramia; Sherene Loi; Genevieve Kerr; Helen E Abud; Georg Ramm; Antonella Papa; Andrew M Ellisdon; Roger J Daly; Catriona A McLean; Christina A Mitchell
Journal:  Nat Commun       Date:  2021-05-25       Impact factor: 14.919

9.  Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.

Authors:  Magdalena Cizkova; Géraldine Cizeron-Clairac; Sophie Vacher; Aurélie Susini; Catherine Andrieu; Rosette Lidereau; Ivan Bièche
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

10.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.